Glucagon-like peptide-1 analogue - CellMed

Drug Profile

Glucagon-like peptide-1 analogue - CellMed

Alternative Names: CM-3; CM3 (second-generation GLP-1) - CellMed; CM3 protein - CellMed; CM3.1; CM3.1-AC100; CM31; Glucagon-like peptide (GLP)-1 analogues for diabetes - CellMed/AstraZeneca

Latest Information Update: 21 Mar 2014

Price : $50

At a glance

  • Originator CellMed
  • Class Glucagon-like peptides; Hormones
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 01 Dec 2013 Discontinued - Phase-I for Type-2 diabetes mellitus in Germany (SC)
  • 01 Dec 2013 Discontinued - Phase-I for Obesity in Germany (SC)
  • 13 May 2011 AstraZeneca terminates its licence for Glucagon-like peptide-1 analogue in for the treatment of type-II diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top